Study For Evaluating The Value Of A Multi Biomarker Approach In Metastatic GEP NETs
NCT ID: NCT02630654
Last Updated: 2021-12-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
404 participants
OBSERVATIONAL
2014-03-24
2021-11-09
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
GEP NETs
Patients with a suspected diagnosis of metastatic GEP NETs
This is a non-interventional study. Patients will be treated with any intervention deemed appropriate by the patient's physician.
Healthy controls
Healthy controls matched by age and gender.
This is a non-interventional study. Patients will be treated with any intervention deemed appropriate by the patient's physician.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
This is a non-interventional study. Patients will be treated with any intervention deemed appropriate by the patient's physician.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Suspected of suffering from a metastatic midgut NET or Pancreatic non-functional NET (WHO grade 1 or 2, up to 10% Ki67).
* Male or female aged 18 or older.
Exclusion Criteria
* Has any mental condition rendering the subject unable to understand the nature, scope and possible consequences of the study, and/or evidence of an uncooperative attitude.
* Suffering from a malignant disease or previously treated for a malignant disease within the last 6 months.
* Suffering from a chronic inflammatory disease.
* Suffering from a renal and/or liver disease.
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ipsen
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ipsen Medical Director
Role: STUDY_DIRECTOR
Ipsen
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Aarhus, , Denmark
Copenhagen, , Denmark
Odense, , Denmark
North Estonia Medical Center
Tallinn, , Estonia
Helsinki, , Finland
Oulu, , Finland
Tampere, , Finland
Pauls Stradins Clinical University Hospital
Riga, , Latvia
Riga East University Hospital
Riga, , Latvia
The Hospital of Lithuanian Health Science
Kaunas, , Lithuania
Klaipėda University Hospital
Klaipėda, , Lithuania
National Cancer Institute
Vilnius, , Lithuania
Vilnius University Hospital
Vilnius, , Lithuania
Bergen, , Norway
Oslo, , Norway
Stavanger, , Norway
Trondheim, , Norway
Gothenburg, , Sweden
Jönköping, , Sweden
Lund, , Sweden
Örebro, , Sweden
Karolinska Universitetssjukhuset Bröst - och Endokrinkirurgiska kliniken
Stockholm, , Sweden
Södersjukhuset
Stockholm, , Sweden
Umeå, , Sweden
Uppsala, , Sweden
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Kjellman M, Knigge U, Welin S, Thiis-Evensen E, Gronbaek H, Schalin-Jantti C, Sorbye H, Joergensen MT, Johanson V, Metso S, Waldum H, Soreide JA, Ebeling T, Lindberg F, Landerholm K, Wallin G, Salem F, Schneider MDP, Belusa R. A Plasma Protein Biomarker Strategy for Detection of Small Intestinal Neuroendocrine Tumors. Neuroendocrinology. 2021;111(9):840-849. doi: 10.1159/000510483. Epub 2020 Jul 28.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
A-99-52030-286
Identifier Type: -
Identifier Source: org_study_id